Large clinical trial will test combination monoclonal antibody therapy for mild/moderate COVID-19

The Phase 2/3 clinical trial will evaluate experimental antibodies BRII-196 and BRII-198.  
Source: National Institutes of Health (NIH) News Releases - Category: American Health Source Type: news